ATE220556T1 - Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori - Google Patents

Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori

Info

Publication number: ATE220556T1
Authority: AT; Austria
Prior art keywords: pct; lactoperoxidase; thiocyanate; helicobacter pylori; medication
Prior art date: 1996-01-23

Application number

AT97901880T

Other languages

English (en)

Inventor

Carl Olof Claesson

Gustaf Lindewald

Original Assignee

Semper Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-23

Filing date

1997-01-22

Publication date

2002-08-15

1997-01-22 Application filed by Semper Ab filed Critical Semper Ab

2002-08-15 Application granted granted Critical

2002-08-15 Publication of ATE220556T1 publication Critical patent/ATE220556T1/de

Links

108010023244 Lactoperoxidase Proteins 0.000 title abstract 2
102000045576 Lactoperoxidases Human genes 0.000 title abstract 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 title abstract 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 title abstract 2
229940057428 lactoperoxidase Drugs 0.000 title abstract 2
150000002978 peroxides Chemical class 0.000 title abstract 2
206010019375 Helicobacter infections Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
230000000844 anti-bacterial effect Effects 0.000 abstract 2
241000590002 Helicobacter pylori Species 0.000 abstract 1
102000010445 Lactoferrin Human genes 0.000 abstract 1
108010063045 Lactoferrin Proteins 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 1
229940078795 lactoferrin Drugs 0.000 abstract 1
235000021242 lactoferrin Nutrition 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Dairy Products (AREA)
Confectionery (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT97901880T 1996-01-23 1997-01-22 Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori ATE220556T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9600233A SE506529C2 (sv)	1996-01-23	1996-01-23	Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
PCT/SE1997/000098 WO1997026908A1 (en)	1996-01-23	1997-01-22	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection

Publications (1)

Publication Number	Publication Date
ATE220556T1 true ATE220556T1 (de)	2002-08-15

Family

ID=20401114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97901880T ATE220556T1 (de)	1996-01-23	1997-01-22	Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori

Country Status (9)

Country	Link
US (1)	US6149908A (de)
EP (1)	EP1007086B1 (de)
JP (1)	JP2000509367A (de)
AT (1)	ATE220556T1 (de)
AU (1)	AU731221B2 (de)
CA (1)	CA2243708C (de)
DE (1)	DE69714083T2 (de)
SE (1)	SE506529C2 (de)
WO (1)	WO1997026908A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19710068A1 (de) *	1997-03-12	1998-09-17	Kramer Axel	Mittel zur Förderung der Mundhygiene und der Mundgesundheit
US5972355A (en) *	1997-09-30	1999-10-26	E-L Management Corp.	Stable compositions containing biologically active components
KR100603088B1 (ko)	1997-11-05	2006-07-20	코퍼트 비.브이.	식물 병원성 미생물에 대한 살충제
US6190667B1 (en)	1998-06-30	2001-02-20	Institut Pasteur	Methods of inhibiting Helicobacter pylori
US6399570B1 (en) *	1999-02-05	2002-06-04	Agennix, Inc.	Antimicrobial/endotoxin neutralizing polypeptide
DE60033019D1 (de) *	1999-03-17	2007-03-08	Morinaga & Co	Arzneimittel, nahrungsmittel, getränke und futter enthaltend eine kakao-komponente
US6342528B1 (en) *	2000-01-18	2002-01-29	Lynntech, Inc.	Control of microbial populations in the gastrointestinal tract of animals
JP5132865B2 (ja) *	2000-08-21	2013-01-30	ジェドダブリュ．ファーヒー	イソチオシアネートを用いたヘリコバクターの治療方法
WO2002069958A1 (de) *	2001-03-01	2002-09-12	Wolfgang Weuffen	Thiocyanationen zur vorbeugung und therapie von bse und ähnlichen erkrankungen beim tier und menschen
US7770577B2 (en)	2001-05-15	2010-08-10	Gregory E Conner	Methods and devices for treating lung dysfunction
US6702998B2 (en) *	2001-05-15	2004-03-09	Gregory E. Conner	Methods and devices for treating lung dysfunction
SE0200876L (sv) *	2002-03-22	2003-09-23	Krister Tano	Nässpray mot öroninflammationer
NZ537089A (en)	2003-02-24	2007-07-27	Morinaga Milk Industry Co Ltd	Interleukin 6 production inhibitor
WO2005018701A1 (en) *	2003-08-25	2005-03-03	Kane Biotech Inc.	Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
CN100480378C (zh)	2004-02-17	2009-04-22	森永乳业株式会社	生产乳过氧化物酶的方法
US20060289354A1 (en) *	2005-06-15	2006-12-28	Buckman Laboratories International, Inc.	Method and composition to control the growth of microorganisms in aqueous systems and on substrates
US20070092502A1 (en) *	2005-09-01	2007-04-26	Allergan, Inc.	Method of Treating Glaucoma
AU2006335883B2 (en) *	2006-01-20	2011-04-28	Morinaga Milk Industry Co., Ltd.	Pharmaceutical composition, food or drink, or feed for intestinal disease
US20070197388A1 (en) *	2006-02-22	2007-08-23	Buckman Laboratories International, Inc.	Haloperoxidase treatment to control algae
EP2081588A1 (de) *	2006-07-03	2009-07-29	Jean-Paul Perraudin	Antimikrobielle zusammensetzung und ihre verwendungen
GB0705557D0 (en) *	2007-03-23	2007-05-02	Stead Richard G	A treatment
CN101977625A (zh) *	2008-03-20	2011-02-16	克里斯特·坦诺	物质在制备治疗感冒药物中的应用
WO2010042834A1 (en)	2008-10-09	2010-04-15	Anadys Pharmaceuticals, Inc.	A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
JP2009215301A (ja) *	2009-04-27	2009-09-24	Morinaga Milk Ind Co Ltd	プロテアーゼ阻害剤
NZ600269A (en) *	2009-05-20	2014-02-28	Dec Int Nz Ltd	Delivery device for treatment of mastitis
US20120315261A1 (en) *	2010-02-24	2012-12-13	Morinaga Milk Industry Co., Ltd.	Antibacterial auxiliary agent comprising kombu extract as active ingredient, antibacterial composition, and food or beverage
US11407713B2 (en)	2011-01-03	2022-08-09	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en)	2011-01-03	2019-04-30	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US8933119B2 (en)	2011-01-03	2015-01-13	The William M. Yarbrough Foundation	Method for treating phytophotodermatitis
US10308599B2 (en)	2011-01-03	2019-06-04	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US9962361B2 (en)	2011-01-03	2018-05-08	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en)	2011-01-03	2022-03-22	The William M. Yarbrough Foundation	Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en)	2011-01-03	2020-05-12	The William M. Yarbrough Foundation	Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en)	2011-01-03	2020-05-05	The William M. Yarbrough Foundation	Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en)	2011-01-12	2014-10-21	The William M. Yarbrough Foundation	Method for treating eczema
US9532969B2 (en)	2011-02-08	2017-01-03	The William M. Yarbrough Foundation	Method for treating psoriasis
US9839621B2 (en)	2012-07-26	2017-12-12	The William M. Yarbrough Foundation	Method for treating bladder cancer
US10080734B2 (en)	2012-07-26	2018-09-25	The William M. Yarbrough Foundation	Method for treating autism and other neurodevelopmental disorders
US10434082B2 (en)	2012-07-26	2019-10-08	The William M. Yarbrough Foundation	Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10441561B2 (en)	2012-07-26	2019-10-15	The William M. Yanbrough Foundation	Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10335387B2 (en)	2012-07-26	2019-07-02	The William M. Yarbrough Foundation	Method for treating infectious diseases with isothiocyanate functional compounds
US8865772B2 (en)	2012-07-26	2014-10-21	The William M. Yarbrough Foundation	Method for treating skin cancer
US10434081B2 (en)	2012-07-26	2019-10-08	The William M. Yarbrough Foundation	Inhibitors of macrophage migration inhibitory factor
US9949943B2 (en)	2012-07-26	2018-04-24	The William M. Yarbrough Foundation	Method for treating neurodegenerative diseases
US20150282489A1 (en)	2012-11-30	2015-10-08	Dsm Ip Assets B.V.	Synergistic fungicidal compositions containing lactoperoxidase system
EP3245871A1 (de) *	2014-04-30	2017-11-22	Matoke Holdings Limited	Antimikrobielle zusammensetzungen
WO2016059654A1 (en) *	2014-10-16	2016-04-21	Giuseppe Baricco	Use of glucose oxidase for the control, the prevention and the cure of intestinal disorders
GB2540130B (en) *	2015-06-29	2021-04-14	Institute Of Tech Sligo	A composition and a method for controlling bacterial infection
GB201716986D0 (en)	2017-10-16	2017-11-29	Matoke Holdings Ltd	Antimicrobial compositions
EP4309500B1 (de)	2022-07-18	2025-06-04	Acies Bio d.o.o.	Biokontrollmittel auf peroxidase-basis
US20250332227A1 (en)	2022-07-18	2025-10-30	Acies Bio D.O.O.	Peroxidase based biocontrol agents
GB2635854B (en) *	2023-11-24	2026-03-18	Killian Obriain	Composition and use thereof for the treatment of watery mouth disease in lambs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE420793B (sv) *	1976-03-08	1981-11-02	Astra Ewos Ab	Fodermedel innehallande ett antibakteriellt system
US4578265A (en) *	1981-08-13	1986-03-25	Laclede Professional Products, Inc.	Di-enzymatic dentifrice
US4564519A (en) *	1983-06-06	1986-01-14	Laclede Professional Products, Inc.	Di-enzymatic chewable dentifrice
DK501686A (da) *	1986-10-20	1988-04-21	Otto Melchior Poulsen	Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
SE469004B (sv) *	1989-03-07	1993-04-26	Nobeltech Electronics Ab	Nattkikare
FR2646777B1 (fr) *	1989-05-12	1993-09-03	Bio Serae Lab	Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications
GB9002422D0 (en) *	1990-02-03	1990-04-04	Boots Co Plc	Anti-microbial compositions
US5453284A (en) *	1993-01-29	1995-09-26	Pellico; Michael A.	Stabilized enzymatic dentifrice
US5336494A (en) *	1993-01-29	1994-08-09	Pellico Michael A	Pet chewable products with enzymatic coating

1996
- 1996-01-23 SE SE9600233A patent/SE506529C2/sv not_active IP Right Cessation
1997
- 1997-01-22 US US09/117,029 patent/US6149908A/en not_active Expired - Fee Related
- 1997-01-22 AT AT97901880T patent/ATE220556T1/de not_active IP Right Cessation
- 1997-01-22 EP EP97901880A patent/EP1007086B1/de not_active Expired - Lifetime
- 1997-01-22 AU AU15627/97A patent/AU731221B2/en not_active Ceased
- 1997-01-22 WO PCT/SE1997/000098 patent/WO1997026908A1/en not_active Ceased
- 1997-01-22 JP JP9526782A patent/JP2000509367A/ja active Pending
- 1997-01-22 CA CA002243708A patent/CA2243708C/en not_active Expired - Fee Related
- 1997-01-22 DE DE69714083T patent/DE69714083T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6149908A (en)	2000-11-21
AU731221B2 (en)	2001-03-29
CA2243708C (en)	2007-04-24
JP2000509367A (ja)	2000-07-25
DE69714083T2 (de)	2003-03-27
EP1007086B1 (de)	2002-07-17
SE506529C2 (sv)	1997-12-22
AU1562797A (en)	1997-08-20
SE9600233D0 (sv)	1996-01-23
SE9600233L (sv)	1997-07-24
CA2243708A1 (en)	1997-07-31
DE69714083D1 (de)	2002-08-22
WO1997026908A1 (en)	1997-07-31
EP1007086A1 (de)	2000-06-14

Legal Events

Date	Code	Title	Description
2003-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69714083D1 (de)	2002-08-22	Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
ATE256475T1 (de)	2004-01-15	Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69636085D1 (de)	2006-06-08	Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
DE69527052D1 (de)	2002-07-18	Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
DE59610355D1 (de)	2003-05-22	Medizinisches implantat
DE69322766D1 (de)	1999-02-04	Formulierung und verwendung von mikroorganismen zur behandlung von vieh
ATE144420T1 (de)	1996-11-15	Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
MY113059A (en)	2001-11-30	Controlled-release dosage forms of azithromycin
DE69533593D1 (de)	2004-11-04	Zubereitungen zur behandlung von gastrointestinalen störungen, welche arabinogalactan und polyphenole von larix enthalten.
DE69526937D1 (de)	2002-07-11	Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE196738T1 (de)	2000-10-15	Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
DE59107536D1 (de)	1996-04-18	Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
ATE190839T1 (de)	2000-04-15	Verwendung von prodelphidinen zur behandlung von arthrose
DE69516110D1 (de)	2000-05-11	Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
DE50100833D1 (de)	2003-11-27	Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE197545T1 (de)	2000-12-15	Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
AU577349B2 (en)	1988-09-22	Vaccine for humans and warm-blooded animals
DE69610045D1 (de)	2000-10-05	Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE207353T1 (de)	2001-11-15	Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69124382D1 (de)	1997-03-06	Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
ATE291353T1 (de)	2005-04-15	Verwendung von milchsaürebakterien bei der herstellung von fermentierten milchprodukten zur behandlung von verringerten immunitätsebenen
DE3865283D1 (de)	1991-11-07	Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
DE69940363D1 (de)	2009-03-19	Verwendung von Pferdemilch zur Herstellung einer Zusammensetzung zur Behandlung von Mund- und Zahnstörungen
FR2782641B1 (fr)	2002-05-10	Medicament homeopathique comprenant un ou plusieurs composants de la nacre
Grad	1972	Science investigates laying on of hands